veverimer

Veverimer is a first-in-class, orally administered, non-absorbed polymer developed for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD)[1][2][3][5]. It is composed of crosslinked, high-molecular-weight polyamines and acts as a hydrochloric acid binder in the gastrointestinal tract[1][6][7]. Upon ingestion, veverimer becomes protonated and selectively binds chloride anions, sequestering hydrochloric acid (HCl) from the stomach. This process leads to increased serum bicarbonate concentrations without introducing exogenous cations such as sodium or potassium[2][5][6]. The HCl-bound polymer is excreted in feces. Veverimer has demonstrated efficacy in raising serum bicarbonate levels and improving physical function in CKD patients with metabolic acidosis during clinical trials; however, it has not received FDA approval as of 2024 due to requests for additional data on clinical benefit[3][5].

Other names

veverimerTRC101TRC-101TRC 101